Opinion|Videos|November 1, 2024
Healthcare Resource Utilization Impact of GPRC5D-Targeted Therapies
Panelists discuss how the use of GPRC5D-targeted therapies impacts healthcare resource utilization in the community setting, including potential changes in hospitalizations, outpatient visits, and supportive care needs.
Advertisement
Episodes in this series
- How does the use of GPRC5D-targeted therapies affect healthcare resource utilization, such as hospitalizations, outpatient visits, and supportive care requirements in the community setting?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
4
Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera
5